TARCEVA erlotinib 150 mg tablet blister pack Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

tarceva erlotinib 150 mg tablet blister pack

roche products pty ltd - erlotinib hydrochloride, quantity: 163.93 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; magnesium stearate; sodium lauryl sulfate; lactose monohydrate; titanium dioxide; hypromellose; hyprolose; macrogol 400 - non-small cell lung cancer: tarceva is indicated for the first-line treatment of patients with advanced (stage iiib) or metastatic (stage iv) non-small cell lung cancer (nsclc) with activating egfr mutations. tarceva is indicated for maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating egfr mutations who have not progressed on first-line chemotherapy. tarceva is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy. pancreatic cancer: tarceva in combination with gemcitabine is indicated for the treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

TARCEVA erlotinib 100 mg tablet blister pack Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

tarceva erlotinib 100 mg tablet blister pack

roche products pty ltd - erlotinib hydrochloride, quantity: 109.29 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; sodium starch glycollate; microcrystalline cellulose; magnesium stearate; lactose monohydrate; titanium dioxide; hypromellose; hyprolose; macrogol 400 - non-small cell lung cancer: tarceva is indicated for the first-line treatment of patients with advanced (stage iiib) or metastatic (stage iv) non-small cell lung cancer (nsclc) with activating egfr mutations. tarceva is indicated for maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating egfr mutations who have not progressed on first-line chemotherapy. tarceva is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy. pancreatic cancer: tarceva in combination with gemcitabine is indicated for the treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

TARCEVA erlotinib 25 mg tablet blister pack Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

tarceva erlotinib 25 mg tablet blister pack

roche products pty ltd - erlotinib hydrochloride, quantity: 27.32 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; lactose monohydrate; sodium lauryl sulfate; sodium starch glycollate; titanium dioxide; hypromellose; hyprolose; macrogol 400 - non-small cell lung cancer: tarceva is indicated for the first-line treatment of patients with advanced (stage iiib) or metastatic (stage iv) non-small cell lung cancer (nsclc) with activating egfr mutations. tarceva is indicated for maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating egfr mutations who have not progressed on first-line chemotherapy. tarceva is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy. pancreatic cancer: tarceva in combination with gemcitabine is indicated for the treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

ERLOTINIB 150MG TABLETAS Panama - angļu - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

erlotinib 150mg tabletas

hetero labs limited - erlotinib (erlotinib clorhidrato 163 - erlotinib (erlotinib clorhidrato 163.900 mg)....150.000mg

Erlotinib STADA 150 mg film-coated tablets Malta - angļu - Medicines Authority

erlotinib stada 150 mg film-coated tablets

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - erlotinib hydrochloride - film-coated tablet - erlotinib hydrochloride 150 mg - antineoplastic agents

Erlotinib Tarbis 150 mg film-coated tablets Malta - angļu - Medicines Authority

erlotinib tarbis 150 mg film-coated tablets

jv healthcare limited navi buidlings, pantar road, lija, lja 2021, malta - erlotinib hydrochloride - film-coated tablet - erlotinib hydrochloride 150 mg - antineoplastic agents

Erlotinib Tablets 150mg "NK" (エルロチニブ錠150mg「NK」) Japāna - angļu - すりの適正使用協議会 RAD-AR Council, Japan

erlotinib tablets 150mg "nk" (エルロチニブ錠150mg「nk」)

nippon kayaku - erlotinib hydrochloride - white to yellowish white tablet (diameter: 9.6mm, thickness: 5.0mm)

Erlotinib Tablets 25mg "NK" (エルロチニブ錠25mg「NK」) Japāna - angļu - すりの適正使用協議会 RAD-AR Council, Japan

erlotinib tablets 25mg "nk" (エルロチニブ錠25mg「nk」)

nippon kayaku - erlotinib hydrochloride - white to yellowish white tablet (diameter: 6.5mm, thickness: 3.2mm)

APO-ERLOTINIB TABLET Kanāda - angļu - Health Canada

apo-erlotinib tablet

apotex inc - erlotinib (erlotinib hydrochloride) - tablet - 25mg - erlotinib (erlotinib hydrochloride) 25mg - antineoplastic agents

APO-ERLOTINIB TABLET Kanāda - angļu - Health Canada

apo-erlotinib tablet

apotex inc - erlotinib (erlotinib hydrochloride) - tablet - 100mg - erlotinib (erlotinib hydrochloride) 100mg - antineoplastic agents